DexCom, Inc. (DXCM) Financial Statements

DexCom, Inc.

DXCM · NASDAQ-GS

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$4.66B	$4.03B	$3.62B	$2.91B	$2.45B	$1.93B	$1.48B	$1.03B
Cost of Revenue	$1.86B	$1.59B	$1.33B	$1.03B	$768.00M	$646.60M	$544.50M	$367.70M
Gross Profit	$2.80B	$2.44B	$2.29B	$1.88B	$1.68B	$1.28B	$931.50M	$663.90M
Research & Development	$599.10M	$552.40M	$505.80M	$484.20M	$517.10M	$359.90M	$273.50M	$199.70M
Selling, General & Administrative	$1.29B	$1.29B	$1.19B	$1.01B	$810.50M	$618.20M	$515.70M	$432.80M
Operating Expenses	$1.89B	$1.84B	$1.69B	$1.49B	$1.41B	$980.60M	$789.20M	$850.20M
Operating Income	$911.80M	$600.00M	$597.70M	$391.20M	$265.80M	$299.50M	$142.30M	-$186.30M
Interest Expense	$14.30M	$14.90M	$20.30M	$18.60M	$18.80M	$17.70M	$60.30M	$22.70M
Other Income / (Expense)	$176.60M	$109.00M	$112.70M	-$400.00K	-$9.00M	$16.10M	$26.40M	$2.40M
Income Before Taxes	$1.09B	$709.00M	$710.40M	$390.80M	$256.80M	$297.90M	$104.20M	-$126.50M
Provision for Income Taxes	$252.10M	$132.80M	$168.90M	$49.60M	$39.90M	-$251.80M	$3.10M	$600.00K
Net Income	$836.30M	$576.20M	$541.50M	$341.20M	$216.90M	$549.70M	$101.10M	-$127.10M
Basic EPS	$2.14	$1.46	$1.40	$0.88	$0.56	$1.46	$1.11	-$1.44
Diluted EPS	$2.09	$1.42	$1.30	$0.82	$0.53	$1.33	$1.10	-$1.44
Basic Shares Outstanding	390.20M	393.60M	386.00M	389.40M	386.90M	377.50M	91.10M	88.20M
Diluted Shares Outstanding	405.50M	412.70M	425.50M	427.50M	428.80M	420.40M	92.30M	88.20M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$2.65	$2.45	$2.70	12	↑11 ↓0
Dec 2027	$3.09	$2.83	$3.29	13	↑11 ↓1
Dec 2028	$3.66	$3.19	$4.10	5	↑4 ↓0
Dec 2029	$3.78	$3.54	$4.02	2	↑1 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: DXCM
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NASDAQ-GS

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Key Issues

Bullish view

Q2 revenue grew 13% year over year, while broader reimbursement access and share gains supported demand. The earnings beat and stronger 2026 guidance indicate that adoption may continue to outpace prior expectations.

Bearish view

The stock’s sharp post-earnings advance has already carried it above the cited average analyst target of $86.11. That valuation response leaves less room for further upside if growth or guidance does not continue improving.

Analyst Consensus

See all

Buy

21 analysts

$83

Current

—

Low

$90

Average

—

High

Average target implies +8.77% versus the current price.

Earnings History

BeatMissNo estimate

Peers

ResMed Inc.RMD · NYSE$222.63